These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Schwartz AG; Prysak GM; Murphy V; Lonardo F; Pass H; Schwartz J; Brooks S Clin Cancer Res; 2005 Oct; 11(20):7280-7. PubMed ID: 16243798 [TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Ramnath N; Menezes RJ; Loewen G; Dua P; Eid F; Alkhaddo J; Paganelli G; Natarajan N; Reid ME Oncology; 2007; 73(5-6):305-10. PubMed ID: 18493157 [TBL] [Abstract][Full Text] [Related]
5. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Minamiya Y; Ogawa J Clin Cancer Res; 2005 Jul; 11(14):5084-9. PubMed ID: 16033821 [TBL] [Abstract][Full Text] [Related]
7. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA; J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216 [TBL] [Abstract][Full Text] [Related]
8. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Slattery ML; Potter JD; Curtin K; Edwards S; Ma KN; Anderson K; Schaffer D; Samowitz WS Cancer Res; 2001 Jan; 61(1):126-30. PubMed ID: 11196149 [TBL] [Abstract][Full Text] [Related]
9. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Stabile LP; Davis AL; Gubish CT; Hopkins TM; Luketich JD; Christie N; Finkelstein S; Siegfried JM Cancer Res; 2002 Apr; 62(7):2141-50. PubMed ID: 11929836 [TBL] [Abstract][Full Text] [Related]
10. Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Chlebowski RT Semin Oncol; 2009 Dec; 36(6):566-71. PubMed ID: 19995648 [TBL] [Abstract][Full Text] [Related]
11. Type and duration of exogenous hormone use affects breast cancer histology. Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262 [TBL] [Abstract][Full Text] [Related]
12. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277 [TBL] [Abstract][Full Text] [Related]
13. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664 [TBL] [Abstract][Full Text] [Related]
14. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Skov BG; Fischer BM; Pappot H Lung Cancer; 2008 Jan; 59(1):88-94. PubMed ID: 17905466 [TBL] [Abstract][Full Text] [Related]
15. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. Wu CT; Chang YL; Shih JY; Lee YC J Thorac Cardiovasc Surg; 2005 Oct; 130(4):979-86. PubMed ID: 16214508 [TBL] [Abstract][Full Text] [Related]
16. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Abe K; Miki Y; Ono K; Mori M; Kakinuma H; Kou Y; Kudo N; Koguchi M; Niikawa H; Suzuki S; Evans DB; Sugawara S; Suzuki T; Sasano H Hum Pathol; 2010 Feb; 41(2):190-8. PubMed ID: 19800101 [TBL] [Abstract][Full Text] [Related]
17. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329 [TBL] [Abstract][Full Text] [Related]
18. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897 [TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Su JM; Hsu HK; Chang H; Lin SL; Chang HC; Huang MS; Tseng HH Anticancer Res; 1996; 16(6B):3803-6. PubMed ID: 9042261 [TBL] [Abstract][Full Text] [Related]
20. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Yang XR; Pfeiffer RM; Garcia-Closas M; Rimm DL; Lissowska J; Brinton LA; Peplonska B; Hewitt SM; Cartun RW; Mandich D; Sasano H; Evans DB; Sutter TR; Sherman ME Cancer Res; 2007 Nov; 67(21):10608-17. PubMed ID: 17968031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]